152 related articles for article (PubMed ID: 14567029)
1. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis.
Elias DM; Sideris L
Surg Oncol Clin N Am; 2003 Jul; 12(3):755-69, xiv. PubMed ID: 14567029
[TBL] [Abstract][Full Text] [Related]
2. Heated intra-operative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: Pharmacologic studies.
Elias D; Raynard B; Bonnay M; Pocard M
Eur J Surg Oncol; 2006 Aug; 32(6):607-13. PubMed ID: 16621432
[TBL] [Abstract][Full Text] [Related]
3. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution.
Elias D; Bonnay M; Puizillou JM; Antoun S; Demirdjian S; El OA; Pignon JP; Drouard-Troalen L; Ouellet JF; Ducreux M
Ann Oncol; 2002 Feb; 13(2):267-72. PubMed ID: 11886004
[TBL] [Abstract][Full Text] [Related]
4. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents.
Sticca RP; Dach BW
Surg Oncol Clin N Am; 2003 Jul; 12(3):689-701. PubMed ID: 14567025
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients.
Elias D; Sideris L; Pocard M; Edè C; Ben Hassouna D; Ducreux M; Boige V; Côté JF; Lasser P
Ann Oncol; 2004 May; 15(5):781-5. PubMed ID: 15111347
[TBL] [Abstract][Full Text] [Related]
6. Peritoneal carcinomatosis of colorectal origin.
Elias D; Raynard B; Farkhondeh F; Goéré D; Rouquie D; Ciuchendea R; Pocard M; Ducreux M
Gastroenterol Clin Biol; 2006 Oct; 30(10):1200-4. PubMed ID: 17075479
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of intraperitoneal cisplatin and doxorubicin.
Rossi CR; Mocellin S; Pilati P; Foletto M; Quintieri L; Palatini P; Lise M
Surg Oncol Clin N Am; 2003 Jul; 12(3):781-94. PubMed ID: 14567031
[TBL] [Abstract][Full Text] [Related]
8. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance.
Elias D; Matsuhisa T; Sideris L; Liberale G; Drouard-Troalen L; Raynard B; Pocard M; Puizillou JM; Billard V; Bourget P; Ducreux M
Ann Oncol; 2004 Oct; 15(10):1558-65. PubMed ID: 15367418
[TBL] [Abstract][Full Text] [Related]
9. The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis.
Gómez Portilla A; Cendoya I; Olabarría I; Martínez de Lecea C; Gómez Martínez de Lecea C; Gil A; Martín E; Muriel J; Magrach L; Romero E; Lirola A; Guede N; Moraza N; Fernández E; Kvadatze M; Valdovinos M; Larrabide I; Ruiz de Alegría N; Fernández JL; Castillo C; Rua O; Ulibarrena MA
Rev Esp Enferm Dig; 2009 Feb; 101(2):97-102, 103-6. PubMed ID: 19335045
[TBL] [Abstract][Full Text] [Related]
10. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
[TBL] [Abstract][Full Text] [Related]
11. Management of peritoneal surface malignancy. Preface.
Sugarbaker PH
Surg Oncol Clin N Am; 2003 Jul; 12(3):xxi-xxiv. PubMed ID: 14567015
[No Abstract] [Full Text] [Related]
12. Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis.
Elias D; El Otmany A; Bonnay M; Paci A; Ducreux M; Antoun S; Lasser P; Laurent S; Bourget P
Oncology; 2002; 63(4):346-52. PubMed ID: 12417789
[TBL] [Abstract][Full Text] [Related]
13. Are there curative options to peritoneal carcinomatosis?
Sugarbaker PH
Ann Surg; 2005 Nov; 242(5):748-50; author reply 750-1. PubMed ID: 16244553
[No Abstract] [Full Text] [Related]
14. HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin.
Elias D; Pocard M; Goere D
Cancer Treat Res; 2007; 134():303-18. PubMed ID: 17633062
[No Abstract] [Full Text] [Related]
15. [Treatment of peritoneal carcinomatosis of non-gynecological origin].
Bagnenko SF; Rukhliada NV; Grinev MV; Beliaev AM
Vestn Khir Im I I Grek; 2002; 161(6):94-9. PubMed ID: 12638508
[No Abstract] [Full Text] [Related]
16. Preliminary results of intraperitoneal chemohyperthermia with oxaliplatin in peritoneal carcinomatosis of colorectal origin.
Elias D; Pocard M; Sideris L; Edè C; Ducreux M; Boige V; Lasser P
Br J Surg; 2004 Apr; 91(4):455-6. PubMed ID: 15048746
[No Abstract] [Full Text] [Related]
17. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
Glockzin G; von Breitenbuch P; Schlitt HJ; Piso P
J Surg Oncol; 2013 May; 107(6):574-8. PubMed ID: 22833286
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer.
Gervais MK; Dubé P; McConnell Y; Drolet P; Mitchell A; Sideris L
J Surg Oncol; 2013 Dec; 108(7):438-43. PubMed ID: 24018983
[TBL] [Abstract][Full Text] [Related]
19. [Preliminary experience with hyperthermic intraperitoneal chemo-perfusion with oxaliplatin for the treatment of peritoneal carcinomatosis due to colorectal carcinoma].
Mura G; Framarini M; Vagliasindi A; Cavaliere D; Tauceri F; Solfrini G; Milandria C; Verdecchia GM
Chir Ital; 2007; 59(2):217-23. PubMed ID: 17500178
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosis.
Valenzuela B; Nalda-Molina R; Bretcha-Boix P; Escudero-Ortíz V; Duart MJ; Carbonell V; Sureda M; Rebollo JP; Farré J; Brugarolas A; Pérez-Ruixo JJ
AAPS J; 2011 Mar; 13(1):72-82. PubMed ID: 21210260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
